Pharmacovigilance – Products
Epilepsy Patients Set To Benefit From Non-Invasive, Real-Time Molecular Breath Analysis
Deep Breath Intelligence is pleased to announce the launch of a simple breath test that can provide reliable estimates of circulating concentrations of the antiseizure medication valproic acid to aid patient management.
VectorBuilder To Invest $30 Million To Build the World’s First "AAV Superbank"
VectorBuilder Inc. has announced its plan to invest $30 million to build an "AAV Superbank" for the research and drug discovery community.
Avacta Announces Second Dose Escalation in the Phase I Clinical Study of AVA6000 Pro-Doxorubicin
Avacta Group plc announces that the first-in-human Phase I trial of AVA6000 Pro-doxorubicin will advance to the third dose cohort following a positive review of the safety data from the dosing of the second cohort.
Precision BioSciences Provides Update on Allogeneic CAR T Programs and Path Forward With its Lead PBCAR0191 Candidate for CAR T Relapsed Patient Population
Precision BioSciences, Inc., has announced its latest program updates across its allogeneic CAR T pipeline.
Waters Introduces High Resolution Mass Spectrometry Products and Software To Accelerate Drug Development
Waters Corporation has unveiled new instruments, software and product enhancements to drive drug discovery and development at the American Society for Mass Spectrometry 2022 Annual Conference.
Agilent Announces the Innovative Seahorse XF Pro Analyzer
Agilent Technologies Inc. has announced the release of the Agilent Seahorse XF Pro Analyzer, featuring new pharma-oriented workflow solutions incorporating advanced experimental design and analysis tools.
Charged Aerosol Detectors - Ensure Vaccine Efficacy
Charged Aerosol detection (CAD) can be used to complement your HPLC-UV analysis in a situation where excipients in a formula are a mix of UV active and inactive components. Using these tools together gives you a robust and reliable analytical detection method to determine the stability of all vaccine excipients.
Protein Biomarkers Show Promise in Predicting Patient Response to Cancer Immunotherapies
Cancer immunotherapy relies on activating or enhancing the antitumor immune response and has taken a central position in cancer treatment modalities. However, not all patients respond to immunotherapy, and combination immunotherapies increase cost of treatment and heighten the risk for toxicity-related adverse events.
SomaScan Assay: The World's Largest Proteomic Platform
Discover more with the first and only technology that can measure 7,000 proteins over a broad range of concentrations. Built on 20 years of pioneering proteomics technology, The SomaScan Assay enables unprecedented biomarker and drug discovery and now, you can seamlessly transition from discovery to validation with new SomaScan panels and SomaSignal TM Tests bolstering the entire drug discovery and development pipeline, all via a straightforward fee-for-service model.
Research Reveals Trivalent PROTACs More Potent in Targeted Protein Degradation
Researchers from the University of Dundee and Promega Corporation have shown how a “three-headed hydra” significantly improves efficacy in targeted protein degradation.